Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.
Malar J
; 10: 141, 2011 May 21.
Article
em En
| MEDLINE
| ID: mdl-21600016
ABSTRACT
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Plasma
/
Piridazinas
/
Proguanil
/
Saquinavir
/
Fármacos Anti-HIV
/
Interações Medicamentosas
/
Atovaquona
/
Antimaláricos
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Malar J
Assunto da revista:
MEDICINA TROPICAL
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Itália